The effect of sertraline on uremic pruritis in hemodialysis patient

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014080918736N1

Enrollment

Registered

2014-09-05

Start date

2014-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uremic pruritus. Chronic kidney disease, unspecified

Interventions

Intervention 1: take sertraline pill the patient recieve setraline 50mg 2 times per day and evaluate in second ans fourth and sixth and eightth week. Intervention 2: take placebo the patient r

Treatment - Drugs

Placebo

take sertraline pill the patient recieve setraline 50mg 2 times per day and evaluate in second ans fourth and sixth and eightth week

take placebo the patient recieve pacebo like setraline 2 times per day and evaluate in second and fourth and sixth and eightth week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: chronic pruritus more than 4 weeks that is resistant to other therapies; do not use lubricating in recent 2 weeks and gabapenthin or antihistamines in recent 1 month; do not have hepatic failure. Excusion criteria: ca*p >55; PTH>500; p>5.5; SLE patients that recieve cellcept or azathioprine.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pruritus. Timepoint: Every 2 for two months. Method of measurement: DOU and VAS score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Maryam Pakfetrat

Shiraz University of Medical Sciences

pakfetratm@sums.ac.ir

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026